A comprehensive view of Shionogi & Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva cabotegravir, rilpivirine is as effective as daily oral Biktarvy BIC/FTC/TAF for the treatment of HIV-1
Published: February 23, 2023 by Business Wire
Japan orders 1 million courses of Japanese drugmaker Shionogi’s oral COVID-19 antiviral Xocova after granting the drug emergency approval; Merck’s Lagevrio, Pfizer’s Paxlovid COVID-19 antivirals previously received approval in the country
Published: December 08, 2022 by Indian Pharma Industry: Policies
Japan approves domestically developed COVID-19 oral antiviral Xocova developed by Shionogi; company to seek US approval for the drug
Published: November 22, 2022 by FiercePharma
ViiV Healthcare announces recipients of largest philanthropic fund in the US dedicated to HIV prevention for Black women; 17 groups awarded grants to raise awareness, connect women to HIV care, drive narrative change among providers
Published: October 07, 2022 by 3BL Media

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count